Homatropine Methylbromide
A quaternary ammonium form of homatropine that does not cross the blood-brain barrier, used as an antispasmodic to reduce gastrointestinal cramping and as an antitussive adjunct. Its reduced central nervous system penetration means it lacks the sedative effects of tertiary anticholinergics. It is used primarily for its peripheral anticholinergic effects on smooth muscle and secretions.
Peso molecular
370,3000 g/mol
TPSA
46,50 Ų
Mecanismo de acción
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(O)c1ccccc1)C2.[Br-]
InChI
InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15+,16?;
Molecular Formula
C17H24BrNO3
HBD / HBA
1 / 4
Enlaces Rotables
4
Átomos Pesados
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A quaternary ammonium form of homatropine that does not cross the blood-brain barrier, used as an antispasmodic to reduce gastrointestinal cramping and as an antitussive adjunct. Its reduced central nervous system penetration means it lacks the sedative effects of tertiary anticholinergics. It is used primarily for its peripheral anticholinergic effects on smooth muscle and secretions.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Homatropine Methylbromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200851. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6646. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="homatropine-methylbromide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/homatropine-methylbromide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/homatropine-methylbromide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/homatropine-methylbromide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="homatropine-methylbromide"></drugfyi-drug>